BRASKEM S.A. reported a Recurring EBITDA of US$557 million for 2025, a 49% decrease from 2024, attributed to reduced demand and lower chemical prices. The company also faced a significant cash consumption of R$7.3 billion, leading to an increased leverage of 14.74x.